Othera announces positive Interim Phase 2 Results of OT-551 Eye Drop Treatment for Dry AMD
OT-551 is a topically-dosed, patented small molecule that acts on oxidative stress and disease-induced inflammation. A number of scientific publications in ophthalmology have linked both oxidative stress and inflammation to the progression of GA and the ensuing vision loss in patients. OT-551 has demonstrated a dose-dependent protective effect on photoreceptor activity in an animal model of AMD, and has been shown to reach the back of the eye after topical dosing in multiple species. This profile supports the rationale for studying the drug in patients with degenerative retinal conditions, such as GA. OT-551 is the first eye drop to ever be tested in a clinical trial as a treatment for dry AMD.
The analysis of drug safety and effectiveness for the entire study population and in subgroups is still in progress. An independent Data and Safety Monitoring Committee is scheduled to review the interim results later this month.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.